Serge P. Parel

Exquiron Biotech AG provides contract research services in early stage drug discovery. Its services include assay development for hit finding and profiling purposes, compound selection, high throughput screening, selectivity testing and hit characterization, and structure activity relationship expansion. The company was founded by Stephan Fasler, Kurt Engeloch, Daniela Brodbeck and Serge P. Parel in 2013 and is headquartered in Reinach, Switzerland.

Exquiron Biotech AG provides contract research services in early stage drug discovery. Its services include assay development for hit finding and profiling purposes, compound selection, high throughput screening, selectivity testing and hit characterization, and structure activity relationship expansion. The company was founded by Stephan Fasler, Kurt Engeloch, Daniela Brodbeck and Serge P. Parel in 2013 and is headquartered in Reinach, Switzerland.

Exquiron Biotech AG provides contract research services in early stage drug discovery. Its services include assay development for hit finding and profiling purposes, compound selection, high throughput screening, selectivity testing and hit characterization, and structure activity relationship expansion. The company was founded by Stephan Fasler, Kurt Engeloch, Daniela Brodbeck and Serge P. Parel in 2013 and is headquartered in Reinach, Switzerland.